Dr Rosalind Wilson
Chief Executive Officer
Biotechnology
Factor Therapeutics
Australia
Biography
Dr Wilson’s career has spanned a variety of senior leadership and advisory roles, from small, innovation-led businesses, to global biopharma, including strategy and portfolio management roles at F.Hoffman-LaRoche (Roche Australia, UK and Switzerland), and Business Manager at NucleusX. At Roche, Dr Wilson notably led the team that developed pertuzumab (Perjeta®) in HER2-overexpressing breast cancer, and was also lifecycle leader for the orlistat (Xenical®) franchise. Dr Wilson is clinically trained and holds an MBBS with first class honours from Monash University, and an MBA with distinction from the London Business School. Prior to joining Factor Therapeutics, Dr Wilson was Executive Officer at the Lung Foundation Australia.
Research Interest
Breast cancer
